Sign in
Taking peoplePhase 4

Two triamcinolone acetonide treatments compared for patchy hair loss from alopecia areata

Compares triamcinolone acetonide injections with microneedling plus triamcinolone acetonide in adults with alopecia areata.

Key facts

Who runs it
Dow University of Health Sciences
Where
Pakistan1 site in 1 countryChoose a country to see its sites
Trial code
Registry title
Comparative Effectiveness of Intralesional Injection of Triamcinolone Acetonide vs. Microneedling With Local Application of Triamcinolone Acetonide in the Treatment of Alopecia Areata
Status
Recruiting
Phase
Phase 4
People taking part
276 people, planned
Started
1 Jan 2026
Expected to end
Dec 2026
Type of study
Interventional, 2 groups
Treatments tested
  • Triamcinolone acetonide
  • Microneedling with topical triamcinolone acetonide
Record updated
9 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with alopecia areata, a condition that causes patchy hair loss. It compares triamcinolone acetonide injections with microneedling plus triamcinolone acetonide put on the skin.

Age
18 years and older
Sex
Men and women
Disease stage
Alopecia areata diagnosed by a doctor, covering 25 percent or less of the scalp. The hair loss has lasted up to 12 months.
Earlier treatment
No immunosuppressive treatment, by mouth, injection or on the skin, in the last 4 weeks. These are medicines that calm the immune system.

Main reasons for not taking part

  • Hair loss on more than 25 percent of the scalp, or total loss of scalp or body hair (alopecia totalis or universalis)
  • Scarring hair loss or an active scalp infection
  • Past keloids (thick raised scars) or problems with wound healing
  • Pregnant or breastfeeding women
  • Known allergy to triamcinolone acetonide or local anesthetics

The registry criteria, word for word

Show all 2 criteriaShow less

Who can take part

  • Male and female participants aged 18 years and above; Clinically diagnosed alopecia areata involving 25 percent or less of the scalp surface area; Disease duration of up to 12 months; Willingness to participate in the study and provide written informed consent

Who cannot take part

  • Extensive alopecia areata involving more than 25 percent of the scalp, alopecia totalis, or alopecia universalis; Scarring alopecia or active scalp infection; History of keloid formation or abnormal wound healing; Pregnant or lactating women; Use of systemic or topical immunosuppressive therapy within the last 4 weeks; Known hypersensitivity to triamcinolone acetonide or local anesthetics; Presence of uncontrolled autoimmune disorders that may affect treatment response

This trial is currently available in Pakistan.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Brief Summary

Read full original descriptionShow less

The goal of this clinical trial is to learn which treatment works better for people with alopecia areata, a condition that causes patchy hair loss. The study will compare two commonly used treatments to see which one leads to better hair regrowth and fewer side effects.

The main questions this study aims to answer are:

Does injecting triamcinolone acetonide into the skin lead to better hair regrowth than microneedling with topical triamcinolone acetonide?

Are there any side effects linked to these treatments?

Researchers will compare two groups of participants. One group will receive intralesional injections of triamcinolone acetonide. The other group will receive microneedling followed by the local application of triamcinolone acetonide. The results will be compared to see which treatment works better for alopecia areata.

Participants will:

Be examined by the research team to confirm the diagnosis of alopecia areata

Receive one of the two treatments as part of the study

Attend follow-up visits so researchers can check hair regrowth and monitor for side effects

The 2 groups in the trial

  • Intralesional Triamcinolone AcetonideTreatment being tested

    Participants in this arm will receive intralesional injections of triamcinolone acetonide into the affected scalp areas at four-week intervals, according to standard clinical practice.

    Treatment: Triamcinolone acetonide and Microneedling with topical triamcinolone acetonide

  • Microneedling with Topical Triamcinolone AcetonideTreatment being tested

    Participants in this arm will undergo microneedling of the affected scalp areas followed by local application of triamcinolone acetonide at four-week intervals.

    Treatment: Triamcinolone acetonide and Microneedling with topical triamcinolone acetonide

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Comparative Effectiveness of Intralesional Injection of Triamcinolone Acetonide vs. Microneedling With Local Application of Triamcinolone Acetonide in the Treatment of Alopecia Areata
Plain-language title
Two triamcinolone acetonide treatments compared for patchy hair loss from alopecia areataGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
9 November 2026